Recent Analysts’ Ratings Updates for OPKO Health (OPK)

Several brokerages have updated their recommendations and price targets on shares of OPKO Health (NASDAQ: OPK) in the last few weeks:

• 9/26/2024 – OPKO Health had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
• 9/20/2024 – OPKO Health had its “outperform” rating reaffirmed by analysts at Barrington Research. They now have a $2.25 price target on the stock.
• 9/17/2024 – OPKO Health had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $3.00 price target on the stock.
• 9/17/2024 – OPKO Health had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.

OPKO Health Stock Up 1.4 %

Shares of OPKO Health stock traded up $0.02 during midday trading on Tuesday, hitting $1.47. The company had a trading volume of 1,758,591 shares, compared to its average volume of 7,450,921. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.36 and a current ratio of 1.63. The stock has a market capitalization of $1.02 billion, a P/E ratio of -4.20 and a beta of 1.63. The company has a 50 day moving average of $1.53 and a 200 day moving average of $1.38. OPKO Health, Inc. has a 52-week low of $0.85 and a 52-week high of $1.75.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.08. The firm had revenue of $182.20 million for the quarter, compared to analysts’ expectations of $184.70 million. OPKO Health had a negative return on equity of 17.67% and a negative net margin of 33.79%. The company’s revenue was down 31.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.03) EPS. On average, equities analysts predict that OPKO Health, Inc. will post -0.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In other OPKO Health news, major shareholder Opko Health, Inc. sold 12,994 shares of the stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $29.35, for a total value of $381,373.90. Following the completion of the sale, the insider now owns 2,971,570 shares in the company, valued at approximately $87,215,579.50. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 636,444 shares of company stock valued at $21,125,127. 47.26% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rubric Capital Management LP lifted its stake in OPKO Health by 800.0% in the second quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock worth $55,528,000 after purchasing an additional 39,486,490 shares during the last quarter. Y.D. More Investments Ltd bought a new stake in OPKO Health in the second quarter worth about $1,840,000. Squarepoint Ops LLC bought a new stake in OPKO Health in the second quarter worth about $592,000. Lazard Asset Management LLC bought a new stake in OPKO Health in the first quarter worth about $258,000. Finally, AWM Investment Company Inc. raised its stake in shares of OPKO Health by 18.2% during the first quarter. AWM Investment Company Inc. now owns 1,300,000 shares of the biotechnology company’s stock valued at $1,560,000 after acquiring an additional 200,000 shares in the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.